Mark Phillips
Compliance Officer bij COGNETIVITY NEUROSCIENCES LTD.
Vermogen: 10 607 $ op 30-04-2024
Profiel
Mark A.
Phillips is currently the Chairman at Cognetivity Ltd., Director & Chief Compliance Officer at Cognetivity Neurosciences Ltd., Non-Executive Director at Fluorogenics Ltd., and Director at Centillion Technology Ltd.
He previously worked as Senior Vice President-Research & Development at GSK Plc.
Phillips holds a doctorate degree from the University of Cambridge and an undergraduate degree from Loughborough University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 09-11-2022 | 815 934 ( 0.91% ) | 10 607 $ | 30-04-2024 |
Actieve functies van Mark Phillips
| Bedrijven | Functie | Begin |
|---|---|---|
| COGNETIVITY NEUROSCIENCES LTD. | Compliance Officer | 21-12-2017 |
Cognetivity Ltd.
 Cognetivity Ltd. BiotechnologyHealth Technology Cognetivity Ltd. engages in the research and experimental development on biotechnology. It focuses on the diagnosis and prognosis of dementia. Its advisory board includes leaders in artificial intelligence, medical diagnostics, old age psychiatry and neurology, cognitive analysis, and brain mapping. The company was founded by Sina Habibi and Seyed Mahdi Khaligh Razavi and is headquartered in London, the United Kingdom. | Voorzitter | 01-01-2014 |
Fluorogenics Ltd.
 Fluorogenics Ltd. Miscellaneous Commercial ServicesCommercial Services Part of New England Biolabs, Inc., Fluorogenics Ltd. is a British company that specializes in sample-to-result integrated analyzers and real-time PCR lyophilized reagents. The company is based in Salisbury, UK. The company brings extensive technical expertise to the market and offers leading performance ambient stable solutions through their ISO 13485:2016 certified facilities and ADMIX custom product service. The company was founded in 2011 by Martin Alan Lee, who has been the CEO since then. Fluorogenics was acquired by New England Biolabs, Inc. on May 10, 2021. | Directeur/Bestuurslid | 01-09-2016 |
| Centillion Technology Ltd. | Directeur/Bestuurslid | 01-01-2021 |
Eerdere bekende functies van Mark Phillips
| Bedrijven | Functie | Einde |
|---|---|---|
| GSK PLC | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Mark Phillips
| University of Cambridge | Doctorate Degree |
| Loughborough University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| GSK PLC | Health Technology |
| COGNETIVITY NEUROSCIENCES LTD. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Cognetivity Ltd.
Cognetivity Ltd. BiotechnologyHealth Technology Cognetivity Ltd. engages in the research and experimental development on biotechnology. It focuses on the diagnosis and prognosis of dementia. Its advisory board includes leaders in artificial intelligence, medical diagnostics, old age psychiatry and neurology, cognitive analysis, and brain mapping. The company was founded by Sina Habibi and Seyed Mahdi Khaligh Razavi and is headquartered in London, the United Kingdom. | Health Technology |
Fluorogenics Ltd.
Fluorogenics Ltd. Miscellaneous Commercial ServicesCommercial Services Part of New England Biolabs, Inc., Fluorogenics Ltd. is a British company that specializes in sample-to-result integrated analyzers and real-time PCR lyophilized reagents. The company is based in Salisbury, UK. The company brings extensive technical expertise to the market and offers leading performance ambient stable solutions through their ISO 13485:2016 certified facilities and ADMIX custom product service. The company was founded in 2011 by Martin Alan Lee, who has been the CEO since then. Fluorogenics was acquired by New England Biolabs, Inc. on May 10, 2021. | Commercial Services |
| Centillion Technology Ltd. |
